Entera Bio Ltd. Long-term assets (Other)

Long-term assets (Other) of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Long-term assets (Other) growth rates and interactive chart. All other non-current assets that do not fit the categories above.

Highlights and Quick Summary

  • Long-term assets (Other) for the quarter ending June 29, 2020 was $214 Thousand (a -14.4% decrease compared to previous quarter)
  • Year-over-year quarterly Long-term assets (Other) decreased by -27.46%
  • Annual Long-term assets (Other) for 2019 was $260 Thousand
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Long-term assets (Other) of Entera Bio Ltd.

Most recent Long-term assets (Other)of ENTX including historical data for past 10 years.

Interactive Chart of Long-term assets (Other) of Entera Bio Ltd.

Entera Bio Ltd. Long-term assets (Other) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $0.21 $0.25
2019 $0.26 $0.3 $0.33 $0.36 $0.26

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.